HRP20090256T1 - Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method - Google Patents
Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive methodInfo
- Publication number
- HRP20090256T1 HRP20090256T1 HR20090256T HRP20090256T HRP20090256T1 HR P20090256 T1 HRP20090256 T1 HR P20090256T1 HR 20090256 T HR20090256 T HR 20090256T HR P20090256 T HRP20090256 T HR P20090256T HR P20090256 T1 HRP20090256 T1 HR P20090256T1
- Authority
- HR
- Croatia
- Prior art keywords
- units
- dienogest
- daily dose
- estradiol valerate
- phase
- Prior art date
Links
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 title abstract 6
- 229960004766 estradiol valerate Drugs 0.000 title abstract 6
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 title abstract 4
- 229960003309 dienogest Drugs 0.000 title abstract 4
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 title abstract 2
- 206010027514 Metrorrhagia Diseases 0.000 title abstract 2
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 229940083544 estradiol 2 mg Drugs 0.000 abstract 1
- 230000002175 menstrual effect Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Primjena estradiolvalerata u kombinaciji s 17α-cijanometil-17-ß-hidroksiestra-4,9-dien-3-onom (dienogest), koja pri tome sadržavaprvu fazu s 2 jedinice dnevne doze estradiolvalerata do 3 mg, drugu fazu s 2 grupe jedinice dnevne doze, pri čemu prva grupa sadržava 5 jedinica dnevne doze kombinacije 2 mg estradiolvalerata i 2 mg dienogesta, i druga grupa sadržava 17 jedinica dnevne doze kombinacije 2 mg estradiolvalerata i 3 mg dienogesta, treću fazu s 2 jedinice dnevne doze s 1 mg estradiolvalerata i jednu daljnju fazu s 2 jedinice dnevne doze farmaceutski neškodljivog placebaza izradu višefaznog kombiniranog pripravka s ukupnim brojem od 28 jedinica dnevne doze za oralnu terapiju disfunkcionalnog uterinog krvarenja, gdje se podrazumijeva menstrualno krvarenje dulje od 7 dana, zajedno s oralnom kontracepcijom.Administration of estradiol valerate in combination with 17α-cyanomethyl-17-ß-hydroxyester-4,9-dien-3-one (dienogest), which contains the first phase with 2 units of daily dose of estradiol valerate up to 3 mg, the second phase with 2 groups of units per day the first group contains 5 units of daily dose of a combination of 2 mg estradiol valerate and 2 mg dienogest, and the second group contains 17 units of daily dose combination of 2 mg estradiol valerate and 3 mg dienogest, the third phase with 2 units of daily dose with 1 mg estradiol valerate and one a further phase with 2 units of daily dose of pharmaceutically innocuous placebo to make a multiphase combined preparation with a total of 28 units of daily dose for oral therapy of dysfunctional uterine bleeding, which means menstrual bleeding longer than 7 days, together with oral contraception.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05022324A EP1787649B1 (en) | 2005-10-13 | 2005-10-13 | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090256T1 true HRP20090256T1 (en) | 2009-06-30 |
Family
ID=35811580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090256T HRP20090256T1 (en) | 2005-10-13 | 2009-05-05 | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP1787649B1 (en) |
| JP (2) | JP5735200B2 (en) |
| KR (2) | KR20080065651A (en) |
| CN (1) | CN101312733A (en) |
| AR (1) | AR056694A1 (en) |
| AT (2) | ATE424828T1 (en) |
| CA (1) | CA2623024C (en) |
| CL (1) | CL2011000283A1 (en) |
| CY (2) | CY1110321T1 (en) |
| DE (2) | DE502005006837D1 (en) |
| DK (2) | DK1787649T3 (en) |
| DO (1) | DOP2006000221A (en) |
| ES (2) | ES2322479T3 (en) |
| HR (1) | HRP20090256T1 (en) |
| ME (1) | ME01056B (en) |
| PE (2) | PE20100090A1 (en) |
| PL (2) | PL1787649T3 (en) |
| PT (2) | PT1787649E (en) |
| SI (2) | SI1787649T1 (en) |
| TW (2) | TWI328453B (en) |
| UY (1) | UY29861A1 (en) |
| WO (1) | WO2007042296A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019743B4 (en) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Multiphase preparation for contraception based on natural estrogen |
| PT1787649E (en) * | 2005-10-13 | 2009-05-08 | Bayer Schering Pharma Ag | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| EP1930010A1 (en) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4429374C1 (en) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component |
| DE19540253C2 (en) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Multi-phase preparation for contraception based on natural estrogens |
| CA2261748A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
| US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
| EP1462106A1 (en) * | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
| DE102004019743B4 (en) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Multiphase preparation for contraception based on natural estrogen |
| PT1787649E (en) * | 2005-10-13 | 2009-05-08 | Bayer Schering Pharma Ag | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
-
2005
- 2005-10-13 PT PT05022324T patent/PT1787649E/en unknown
- 2005-10-13 DK DK05022324T patent/DK1787649T3/en active
- 2005-10-13 AT AT05022324T patent/ATE424828T1/en active
- 2005-10-13 PL PL05022324T patent/PL1787649T3/en unknown
- 2005-10-13 ES ES05022324T patent/ES2322479T3/en active Active
- 2005-10-13 ME MEP-2009-171A patent/ME01056B/en unknown
- 2005-10-13 EP EP05022324A patent/EP1787649B1/en not_active Revoked
- 2005-10-13 SI SI200530672T patent/SI1787649T1/en unknown
- 2005-10-13 DE DE502005006837T patent/DE502005006837D1/en active Active
-
2006
- 2006-10-12 DE DE502006008853T patent/DE502006008853D1/en active Active
- 2006-10-12 PT PT06806225T patent/PT1933843E/en unknown
- 2006-10-12 EP EP06806225A patent/EP1933843B1/en active Active
- 2006-10-12 CA CA2623024A patent/CA2623024C/en active Active
- 2006-10-12 PL PL06806225T patent/PL1933843T3/en unknown
- 2006-10-12 PE PE2009001256A patent/PE20100090A1/en not_active Application Discontinuation
- 2006-10-12 WO PCT/EP2006/009867 patent/WO2007042296A1/en active Application Filing
- 2006-10-12 TW TW095137564A patent/TWI328453B/en active
- 2006-10-12 DK DK06806225.6T patent/DK1933843T3/en active
- 2006-10-12 CN CNA2006800381810A patent/CN101312733A/en active Pending
- 2006-10-12 KR KR1020087011203A patent/KR20080065651A/en not_active Application Discontinuation
- 2006-10-12 SI SI200630991T patent/SI1933843T1/en unknown
- 2006-10-12 KR KR1020107014574A patent/KR101218872B1/en active IP Right Grant
- 2006-10-12 PE PE2006001241A patent/PE20070555A1/en not_active Application Discontinuation
- 2006-10-12 JP JP2008534936A patent/JP5735200B2/en active Active
- 2006-10-12 ES ES06806225T patent/ES2360302T3/en active Active
- 2006-10-12 AT AT06806225T patent/ATE497387T1/en active
- 2006-10-13 DO DO2006000221A patent/DOP2006000221A/en unknown
- 2006-10-13 UY UY29861A patent/UY29861A1/en not_active Application Discontinuation
- 2006-10-13 AR ARP060104489A patent/AR056694A1/en not_active Application Discontinuation
-
2007
- 2007-01-09 TW TW096100872A patent/TW200829255A/en unknown
-
2009
- 2009-05-05 HR HR20090256T patent/HRP20090256T1/en unknown
- 2009-06-11 CY CY20091100621T patent/CY1110321T1/en unknown
-
2011
- 2011-02-10 CL CL2011000283A patent/CL2011000283A1/en unknown
- 2011-05-02 CY CY20111100422T patent/CY1111406T1/en unknown
-
2012
- 2012-11-19 JP JP2012253067A patent/JP2013047269A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20070188B1 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| EA200900491A1 (en) | USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN | |
| AR049112A1 (en) | COMPOSITIONS, METHODS AND KIT, FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER | |
| ES2693085T1 (en) | Use of estriol in low doses | |
| PT836506E (en) | TRANSDERMAL PENSION FOR ADMINISTRATION OF 17-DECACEACY NORGESTIMATE SO OR IN COMBINATION WITH A ESTROGEN | |
| JP2009512658A5 (en) | ||
| CA2468748A1 (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| HRP20100513T1 (en) | Multi-phase contraceptive preparation based on a natural estrogen | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| UA81387C2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| EA200701389A1 (en) | SOLID ORAL MEDICAL FORM FOR CONTRACEPTION | |
| NO20072687L (en) | Pharmaceutical contraceptive preparation | |
| RS50849B (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| CY1112775T1 (en) | USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA | |
| UY29378A1 (en) | PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION | |
| PE20091020A1 (en) | USE OF A GESTAGEN IN COMBINATION WITH A ESTROGEN AND ONE OR MORE PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS / CARRIERS FOR LACTOSE-FREE ORAL CONTRACEPTION | |
| CO5200771A1 (en) | A PHARMACEUTICAL COMPOSITION TO BE USED AS AN CONTRACEPTIVE AGENT | |
| JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive |